Medication-assisted treatment for opioid addiction: Methadone and buprenorphine

Journal of Food and Drug Analysis

Volumn 21, Issue 4 SUPPL., 2013, Pages

  Saxon, Andrew J ^a,b   Hser, Yih Ing ^c   Woody, George ^d   Ling, Walter ^c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Buprenorphine; Medication assisted treatment; Methadone; Opioid addiction

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHADONE TREATMENT; OPIATE ADDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEXUALITY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84897029132     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfda.2013.09.037     Document Type: Conference Paper

References (24)

1. Leavitt SB, Shinderman M, Maxwell S, et al. When "enough" is not enough: New perspectives on optimal methadone maintenance dose. Mt Sinai J Med 2000;67:404-11.
2. Ferrari A, Coccia CP, Bertolini A, et al. Methadoneemetabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-9.
3. Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther 1972;13:633-7.
4. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-93.
5. Moody DE, Alburges ME, Parker RJ, et al. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alphaacetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997;5:1347-53.
6. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001;21:229-34.
7. Strain EC, Bigelow GE, Liebson IA, et al. Moderate- vs highdose methadone in the treatment of opioid dependence: A randomized trial. JAMA 1999;281:1000-5.
8. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;70:S13-27.
9. Johnson RE, Strain EC, Amass L. Buprenorphine: How to use it right. Drug Alcohol Depend 2003;70:S59-77.
10. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-80.
11. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005;94:825-34.
12. Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010;105:709-18.
13. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA 2010;304:1576-83.
14. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70:S39-47.
15. Nath RP, Upton RA, Everhart ET, et al. Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999;39:619-23.
16. Compton P, Ling W, Moody D, et al. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 2006;82:25-31.
17. Strain EC, Moody DE, Stoller KB, et al. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 2004;74:37-43.
18. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9.
19. Elkader A, Sproule B. Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005;44:661-80.
20. Walsh SL, June HL, Schuh KJ, et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995;119:268-76.
21. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 2003;361:662-8.
22. Gunne LM, Gronbladh L. The Swedish methadone maintenance program: A controlled study. Drug Alcohol Depend 1981;7:249-56.
23. Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug Alcohol Depend 2013;128:71-6.
24. Hser YI, Saxon AJ, Huang DY, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. In Press.